Drug
Enoxaparine
Enoxaparine is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
20%
Ph phase_4
2
40%
Ph phase_2
1
20%
Ph phase_3
1
20%
Phase Distribution
1
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Other(1)
Detailed Status
Completed4
Suspended1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
Phase 42 (40.0%)
Trials by Status
completed480%
suspended120%
Recent Activity
0 active trials
Showing 5 of 5
suspendedphase_3
Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients
NCT02271295
completedphase_4
The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients
NCT00351663
completedphase_2
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
NCT00402467
completedphase_1
Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer
NCT01945879
completedphase_4
HENOX: Enoxaparine in Hemodialysis
NCT00347490
Clinical Trials (5)
Showing 5 of 5 trials
NCT02271295Phase 3
Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients
NCT00351663Phase 4
The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients
NCT00402467Phase 2
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
NCT01945879Phase 1
Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer
NCT00347490Phase 4
HENOX: Enoxaparine in Hemodialysis
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5